These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 29325495)

  • 1. Management of cancer-associated venous thromboembolism - a case-based practical approach.
    Voigtlaender M; Langer F
    Vasa; 2018 Feb; 47(2):77-89. PubMed ID: 29325495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct oral anticoagulants and venous thromboembolism.
    Franchini M; Mannucci PM
    Eur Respir Rev; 2016 Sep; 25(141):295-302. PubMed ID: 27581829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants.
    Rosovsky R; Merli G
    Tech Vasc Interv Radiol; 2017 Sep; 20(3):141-151. PubMed ID: 29029708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach.
    Black SA; Cohen AT
    Thromb Haemost; 2015 Oct; 114(4):660-9. PubMed ID: 26084864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.
    Haas S; Ageno W; Weitz JI; Goldhaber SZ; Turpie AGG; Goto S; Angchaisuksiri P; Dalsgaard Nielsen J; Kayani G; Zaghdoun A; Farjat AE; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK
    J Thromb Haemost; 2019 Oct; 17(10):1694-1706. PubMed ID: 31220403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.
    Trujillo-Santos J; Di Micco P; Dentali F; Douketis J; Díaz-Peromingo JA; Núñez MJ; Cañas I; Mastroiacovo D; Saraiva de Sousa M; Monreal M;
    Thromb Haemost; 2017 Jan; 117(2):382-389. PubMed ID: 27786333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
    Prandoni P; Barbar S; Milan M; Campello E; Spiezia L; Piovella C; Pesavento R
    Thromb Haemost; 2015 Jun; 113(6):1210-5. PubMed ID: 25119194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulodexide for the extended treatment of venous thromboembolism.
    Walenga JM; Fareed J; Ramacciotti E
    Int Angiol; 2016 Dec; 35(6):531-533. PubMed ID: 27680735
    [No Abstract]   [Full Text] [Related]  

  • 10. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
    Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
    Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal duration of anticoagulation in patients with unprovoked venous thromboembolism: the impact of novel anticoagulants.
    Prandoni P; Milan M; Sarolo L; Zanon E; Bilora F
    Int Angiol; 2017 Oct; 36(5):395-401. PubMed ID: 27982558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-associated venous thromboembolism: Burden, mechanisms, and management.
    Ay C; Pabinger I; Cohen AT
    Thromb Haemost; 2017 Jan; 117(2):219-230. PubMed ID: 27882374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
    Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
    J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
    Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
    Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of venous thromboembolism in patients with cancer.
    López-Núñez JJ; Trujillo-Santos J; Monreal M
    J Thromb Haemost; 2018 Dec; 16(12):2391-2396. PubMed ID: 30246407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of pregnancy-associated venous thromboembolism - position paper from the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH).
    Linnemann B; Scholz U; Rott H; Halimeh S; Zotz R; Gerhardt A; Toth B; Bauersachs R;
    Vasa; 2016; 45(2):103-18. PubMed ID: 27058796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
    Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
    Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
    Pernod G; Joly M; Sonnet B
    J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients.
    Song AB; Rosovsky RP; Connors JM; Al-Samkari H
    Vasc Health Risk Manag; 2019; 15():175-186. PubMed ID: 31417269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
    Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.